PapGene, Inc., a privately-held company commercializing advanced molecular tests, announced that it was recently awarded a highly competitive Fast-Track Small Business Innovation Research (SBIR) grant from the National Cancer Institute of the National Institutes of Health to commercialize a test to detect ovarian and endometrial cancers.
The funds for this Fast-Track grant will be released in two phases, which together have the potential to provide a total of nearly $2.3 million in resources to PapGene’s test commercialization efforts. Phase I will provide $297,000 to the company to demonstrate the accuracy of the test and its clinical validity. Upon successful completion of Phase I, Phase II will provide approximately $2 million to demonstrate the clinical utility of the test and to launch its regulatory approval process.